Servier and Treventis Teaming Up to Develop Therapies That Can Circumvent Protein Misfolding

Servier and Treventis Teaming Up to Develop Therapies That Can Circumvent Protein Misfolding
Servier and Treventis will work together on therapies that can circumvent the misfolded proteins involved in Alzheimer’s and other neurodegenerative diseases. The goal is to develop compounds that prevent the brain’s accumulation of two faulty proteins associated with the disorders — amyloid beta and tau. Servier is an international pharmaceutical concern led by a non-profit foundation based in France. Treventis

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *